Plus   Neg

Novartis Issues Update On Its R&D Pipeline - Quick Facts

At the R&D Day, Novartis AG (NVS) stated that approximately 90 innovative new molecular entities are emerging from the Novartis Institutes for BioMedical Research. Novartis said the company has established leadership in three advanced therapy platforms: cell, gene and radioligand therapies, with a total of 16 advanced platform therapies now in clinical development.

The company is prioritizing emerging assets that address significant unmet need. These include iscalimab in transplant and Sjögren's syndrome, LNP023 in renal diseases and PNH, MBG453 in MDS, and TQJ230 in cardiovascular risk reduction. They will be advanced into pivotal trials in the coming years.

Novartis has 60 projects in phase 2 pipeline with more than 10 advancing into phase 3 or pivotal trials each year in 2020 and 2021. Anticipated near-term launches include ofatumumab in relapsing MS, fevipiprant in asthma, radioligand therapy Lu-PSMA-617 in prostate cancer, Adakveo in sickle cell disease and canakinumab in lung cancer.

The company is exploring over 40 new indications for in-market brands, including up to 7 for Cosentyx alone, and others for Beovu, Piqray and Kisqali.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT